|
Mar 7
|
REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants
|
|
Mar 6
|
REGENXBIO Announces Proposed Public Offering of Common Stock
|
|
Mar 6
|
REGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study
|
|
Mar 6
|
Regenxbio data suggest ‘niche’ in Duchenne gene therapy
|
|
Mar 5
|
REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIAL
|
|
Jan 31
|
REGENXBIO Announces Presentations at the 20th Annual WORLDSymposium 2024
|
|
Jan 16
|
REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery
|
|
Jan 10
|
REGENXBIO Announces Presentation at the Hawaiian Eye and Retina 2024 Meeting
|
|
Jan 9
|
Down -25.53% in 4 Weeks, Here's Why You Should You Buy the Dip in Regenxbio (RGNX)
|
|
Dec 22
|
Regenxbio Inc President and CEO Kenneth Mills Sells 45,000 Shares
|
|
Nov 29
|
REGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE® Trial
|
|
Aug 23
|
REGENXBIO Announces Presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023
|
|
Jun 27
|
REGENXBIO to Host Virtual Investor Day Highlighting AAV Pipeline Programs with Upcoming Interim Trial Updates
|
|
Apr 26
|
REGENXBIO to Host Conference Call on May 3 to Discuss First Quarter 2023 Financial Results and Recent Operational Highlights
|